34729076|PMC8506257
{'Chemical', 'Disease', 'Species', 'Gene'}
In a few months after the global outbreak of coronavirus 19(COVID-19), >109,000 patients in Iran, were confirmed to be infected by this new emerging virus. Hence, ambivalence may occur when MS patients and their physicians confront clinical issues regarding start, stop, or switching MS treatments during the COVID-19 pandemic. Providing thorough information about each treatment, side effects, as well as the risk of infection, will warrant more adherence during the time of the pandemic.